0IV3 Stock Overview
A late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Geron Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.10 |
| 52 Week High | US$5.34 |
| 52 Week Low | US$1.75 |
| Beta | 0.51 |
| 11 Month Change | 2.25% |
| 3 Month Change | -11.07% |
| 1 Year Change | 113.11% |
| 33 Year Change | 175.20% |
| 5 Year Change | 188.38% |
| Change since IPO | 102.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0IV3 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 10.7% | 2.0% | 1.7% |
| 1Y | 113.1% | -17.5% | 8.3% |
Return vs Industry: 0IV3 exceeded the UK Biotechs industry which returned -17.5% over the past year.
Return vs Market: 0IV3 exceeded the UK Market which returned 8.3% over the past year.
Price Volatility
| 0IV3 volatility | |
|---|---|
| 0IV3 Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0IV3 has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0IV3's weekly volatility has decreased from 16% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 141 | Chip Scarlett | www.geron.com |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Geron Corporation Fundamentals Summary
| 0IV3 fundamental statistics | |
|---|---|
| Market cap | US$2.46b |
| Earnings (TTM) | -US$201.19m |
| Revenue (TTM) | US$29.48m |
83.5x
P/S Ratio-12.2x
P/E RatioIs 0IV3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0IV3 income statement (TTM) | |
|---|---|
| Revenue | US$29.48m |
| Cost of Revenue | US$112.38m |
| Gross Profit | -US$82.90m |
| Other Expenses | US$118.29m |
| Earnings | -US$201.19m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.33 |
| Gross Margin | -281.22% |
| Net Profit Margin | -682.47% |
| Debt/Equity Ratio | 28.7% |
How did 0IV3 perform over the long term?
See historical performance and comparison